Alkermes plc · ALKS
$294M
$324M
$279M
$276M
$252M
$305M
$288M
$617M
$381M
$377M
$350M
$399M
$378M
$430M
$307M
$391M
$394M
$385M
$393M
—
20-quarter listed-company comparison
Drug Manufacturers - Specialty & Generic Stocks
Drug Manufacturers - Specialty & Generic: Viatris Inc. owns the largest revenue base; Liquidia Corporation has the fastest current growth.
01 · the industry itself · before any single company
How has Drug Manufacturers - Specialty & Generic moved against S&P 500?
The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the most recent two of them this industry is 42% ahead of S&P 500. Earnings across its companies fell 9% on average over the last four reported quarters.
FADING · −3 in 4w~Price up, without the fundamentals confirming15 of 50 companies ahead of S&P 500 by 5% or more over three months1 is 20% or more behind over a year while earnings grew 20% or more
RS — · 25/50 >200d (−3) · 15/50 lead (−3) · EPS 31/50↑
Drug Manufacturers - Specialty & Generic, equal-weighted, based at 200
S&P 500, same base, same start
trailing 12-month earnings per share rising
falling
Drug Manufacturers - Specialty & Generic, equal-weighted, based at 200
S&P 500, same base, same start
trailing 12-month earnings per share rising
falling
Drug Manufacturers - Specialty & Generic, equal-weighted, based at 200
S&P 500, same base, same start
trailing 12-month earnings per share rising
falling
Both lines start at 200 in the same week, so the distance between them is the whole story: the industry line is an equal-weighted index of its 50 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member rebased to 100 at the start and the industry taking the median — so a price line pulling away from flat bars is a re-rating, not earnings. A bar turns red when that figure is lower than the quarter before. Rules are fixed and applied identically everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover any point to read both values and the gap. This is a description of what the numbers did, not advice.
02 · sector relative strength, before individual stocks
Is Drug Manufacturers - Specialty & Generic outperforming S&P 500?
Drug Manufacturers - Specialty & Generic has outperformed S&P 500 by 15% over the last 52 weeks. Over 13 weeks the gap is a lead of 1.6%. 13 of 28 covered companies currently beat the S&P 500 on Mansfield relative strength, so leadership inside the sector is selective. Liquidia Corporation is the strongest against the sector itself at +86.6%.
+1.6%Sector vs S&P 500 · 13 weeks
+15.0%Sector vs S&P 500 · 52 weeks
13/28Stocks leading S&P 500
10/28Stocks leading sector
Sector metric: — as of latest available · unclassified · direction unavailable.
The central tension: the companies with the most scale are not necessarily the companies creating the most change.
Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.
Bottom line
Drug Manufacturers - Specialty & Generic has outperformed S&P 500 by 15% over 52 weeks and 1.6% over 13 weeks. 13 of 28 covered companies beat the S&P 500 on Mansfield relative strength, while 10 of 28 beat the sector itself. Viatris Inc. leads with revenue of $14,563 million, based on 17 of 28 comparable companies through Mar 2026.
Companies
28
complete canonical membership
Combined market value
$260.8B
Haleon plc
Revenue growing
13/17
positive TTM year-on-year growth
Beating S&P 500
13/28
positive Mansfield relative strength
Comparing 5 of 28
03 · research priority, made explicit
4-Factor Sector Score
An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.
Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%
Liquidia Corporation has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 63.6% evidence confidence.
Lantheus Holdings, Inc. looks inexpensive relative to peers or its own history, but its earnings trajectory has not yet earned the valuation signal.
Lantheus Holdings, Inc. has stronger price confirmation than earnings confirmation; that is a research prompt, not permission to chase.
How this score is built, and what the marks mean
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Liquidia CorporationLQDA | 72.3/100Favorable setup64% evidence | LEADER | 25.7/35 Revenue 100% · PAT — · OPM change 1181.7 pp 62% evidence | 18.0/25 ROCE 29.4% · OPM 46.3% 76% evidence | 8.6/20 P/E 269.6× · PEG — 15% evidence | 20.0/20 RS sector 86.6% · RS bench 89.6% · 1Y 332.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 25.7 + 18 + 8.6 + 20 = 72.3 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Indivior Pharmaceuticals, Inc.INDV | 63.8/100Mixed-positive evidence64% evidence | FADING | 24.0/35 Revenue 10.3% · PAT — · OPM change 18.4 pp 62% evidence | 21.0/25 ROCE 34.8% · OPM 43.2% 76% evidence | 11.4/20 P/E 3.1× · PEG — 15% evidence | 7.4/20 RS sector -1.2% · RS bench 0.8% · 1Y 65.9%8 of 12 weeks ahead 100% evidence |
| Exact sum: 24 + 21 + 11.4 + 7.4 = 63.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Amneal Pharmaceuticals, Inc.AMRX | 60.6/100Thin evidence · provisional58% evidence | BREAKING OUT | 19.6/35 Revenue — · PAT — · OPM change 5.2 pp 45% evidence | 13.3/25 ROCE 5% · OPM 19.6% 76% evidence | 9.8/20 P/E 35.3× · PEG — 15% evidence | 17.9/20 RS sector 26.4% · RS bench 28.8% · 1Y 116.4%9 of 12 weeks ahead 100% evidence |
| Exact sum: 19.6 + 13.3 + 9.8 + 17.9 = 60.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Kiniksa Pharmaceuticals International, plcKNSA | 59.2/100Thin evidence · provisional58% evidence | BREAKING OUT | 19.3/35 Revenue — · PAT — · OPM change 4.1 pp 45% evidence | 12.0/25 ROCE 4.3% · OPM 13.7% 76% evidence | 9.1/20 P/E 101.5× · PEG — 15% evidence | 18.8/20 RS sector 45.1% · RS bench 47.9% · 1Y 136.4%7 of 12 weeks ahead 100% evidence |
| Exact sum: 19.3 + 12 + 9.1 + 18.8 = 59.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Lantheus Holdings, Inc.LNTH | 58.0/100Mixed-positive evidence81% evidence | FADING | 13.6/35 Revenue 0.6% · PAT 9.8% · OPM change -5.8 pp 83% evidence | 14.1/25 ROCE 4.3% · OPM 21.6% 76% evidence | 14.3/20 P/E 18.3× · PEG 1.02 65% evidence | 16.0/20 RS sector 20% · RS bench 22.2% · 1Y 76.8%11 of 12 weeks ahead 100% evidence |
| Exact sum: 13.6 + 14.1 + 14.3 + 16 = 58 · Decision use: Price leads the evidence: RS versus the benchmark is 22.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 6Neurocrine Biosciences, Inc.NBIX | 56.7/100Thin evidence · provisional58% evidence | FADING | 19.5/35 Revenue — · PAT — · OPM change 19.6 pp 45% evidence | 14.0/25 ROCE 3.9% · OPM 23.7% 76% evidence | 10.0/20 P/E 24.7× · PEG — 15% evidence | 13.2/20 RS sector 0.5% · RS bench 2.9% · 1Y 32.8%11 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 14 + 10 + 13.2 = 56.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Phibro Animal Health CorporationPAHC | 55.9/100Mixed-positive evidence75% evidence | ASLEEP | 25.5/35 Revenue 26.1% · PAT 100% · OPM change 2 pp 83% evidence | 13.3/25 ROCE 4% · OPM 11.6% 76% evidence | 12.1/20 P/E 23.7× · PEG 1.31 65% evidence | 5.0/20 RS sector -22.4% · RS bench -20.8% · 1Y 30.2%0 of 12 weeks ahead 70% evidence |
| Exact sum: 25.5 + 13.3 + 12.1 + 5 = 55.9 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -22.4% and the one-year return is 30.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 8Xeris Biopharma Holdings, Inc.XERS | 53.7/100Thin evidence · provisional58% evidence | BREAKING OUT | 24.5/35 Revenue 41.9% · PAT — · OPM change 14.6 pp 62% evidence | 8.8/25 ROCE 3.2% · OPM 9.5% 76% evidence | 9.3/20 P/E 96.7× · PEG — 15% evidence | 11.1/20 RS sector -0.7% · RS bench 1.7% · 1Y 19.7%9 of 12 weeks ahead 70% evidence |
| Exact sum: 24.5 + 8.8 + 9.3 + 11.1 = 53.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Haleon plcHLN | 52.6/100Thin evidence · provisional56% evidence | TURNING | 20.2/35 Revenue — · PAT — · OPM change 9.1 pp 39% evidence | 13.3/25 ROCE 2.2% · OPM 21.8% 76% evidence | 10.8/20 P/E 19.3× · PEG — 15% evidence | 8.3/20 RS sector -11.9% · RS bench -10% · 1Y 2.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 20.2 + 13.3 + 10.8 + 8.3 = 52.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10Viatris Inc.VTRS | 51.2/100Mixed-positive evidence64% evidence | FADING | 21.8/35 Revenue 1.6% · PAT — · OPM change 86.3 pp 62% evidence | 7.7/25 ROCE -0.3% · OPM -2.3% 76% evidence | 8.7/20 P/E 216.6× · PEG — 15% evidence | 13.0/20 RS sector 17.5% · RS bench 19.7% · 1Y 82.5%7 of 12 weeks ahead 100% evidence |
| Exact sum: 21.8 + 7.7 + 8.7 + 13 = 51.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Trulieve Cannabis Corp.TRLV | 50.1/100Mixed-positive evidence64% evidence | FADING | 16.3/35 Revenue -1.4% · PAT — · OPM change 0.6 pp 62% evidence | 11.7/25 ROCE 5.6% · OPM 12.4% 76% evidence | 11.5/20 P/E -13.3× · PEG — 15% evidence | 10.6/20 RS sector 1% · RS bench 3.3% · 1Y 55.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 16.3 + 11.7 + 11.5 + 10.6 = 50.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12ANI Pharmaceuticals, Inc.ANIP | 48.8/100Mixed-negative evidence64% evidence | ASLEEP | 22.5/35 Revenue 36.9% · PAT — · OPM change 3.1 pp 62% evidence | 11.4/25 ROCE 3.4% · OPM 16.4% 76% evidence | 10.6/20 P/E 19.5× · PEG — 15% evidence | 4.3/20 RS sector -16.5% · RS bench -14.4% · 1Y -2.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 22.5 + 11.4 + 10.6 + 4.3 = 48.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Alkermes plcALKS | 48.4/100Thin evidence · provisional58% evidence | LEADER | 12.4/35 Revenue — · PAT — · OPM change -16.8 pp 45% evidence | 8.3/25 ROCE 0.7% · OPM -12.3% 76% evidence | 8.9/20 P/E 132.8× · PEG — 15% evidence | 18.8/20 RS sector 26.8% · RS bench 29.3% · 1Y 86%12 of 12 weeks ahead 100% evidence |
| Exact sum: 12.4 + 8.3 + 8.9 + 18.8 = 48.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Teva Pharmaceutical Industries LimitedTEVA | 47.3/100Thin evidence · provisional58% evidence | ASLEEP | 16.5/35 Revenue — · PAT — · OPM change 4.2 pp 45% evidence | 9.3/25 ROCE -0.9% · OPM 33.7% 76% evidence | 9.5/20 P/E 56.5× · PEG — 15% evidence | 12.0/20 RS sector 6.2% · RS bench 8.1% · 1Y 110.3%1 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 9.3 + 9.5 + 12 = 47.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15Zoetis Inc.ZTS | 45.8/100Mixed-negative evidence81% evidence | BASING | 15.2/35 Revenue 2.6% · PAT 5.8% · OPM change -1.5 pp 83% evidence | 17.1/25 ROCE 6.7% · OPM 35.4% 76% evidence | 8.9/20 P/E 19.6× · PEG 2.03 65% evidence | 4.6/20 RS sector -43.3% · RS bench -41.9% · 1Y -48.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.2 + 17.1 + 8.9 + 4.6 = 45.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Bausch Health Companies Inc.BHC | 44.9/100Thin evidence · provisional58% evidence | TURNING | 16.0/35 Revenue — · PAT — · OPM change -49.8 pp 45% evidence | 8.9/25 ROCE 3.5% · OPM -37.6% 76% evidence | 11.0/20 P/E 16.5× · PEG — 15% evidence | 9.0/20 RS sector -7.7% · RS bench -5.4% · 1Y 12%2 of 12 weeks ahead 100% evidence |
| Exact sum: 16 + 8.9 + 11 + 9 = 44.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Elanco Animal Health IncorporatedELAN | 43.3/100Mixed-negative evidence71% evidence | TURNING | 15.9/35 Revenue 10.5% · PAT -164.9% · OPM change 2.1 pp 83% evidence | 8.8/25 ROCE 1.2% · OPM 10.5% 76% evidence | 8.5/20 P/E 335.7× · PEG — 15% evidence | 10.1/20 RS sector -0.5% · RS bench 1.5% · 1Y 53.6%2 of 12 weeks ahead 100% evidence |
| Exact sum: 15.9 + 8.8 + 8.5 + 10.1 = 43.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18United Therapeutics CorporationUTHR | 42.7/100Mixed-negative evidence81% evidence | ASLEEP | 15.0/35 Revenue 5.9% · PAT 6.5% · OPM change -6.5 pp 83% evidence | 16.5/25 ROCE 5% · OPM 41.7% 76% evidence | 6.3/20 P/E 21.9× · PEG 2.7 65% evidence | 4.9/20 RS sector -6.7% · RS bench -4.8% · 1Y 72.1%2 of 12 weeks ahead 100% evidence |
| Exact sum: 15 + 16.5 + 6.3 + 4.9 = 42.7 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 19Prestige Consumer Healthcare Inc.PBH | 42.6/100Mixed-negative evidence71% evidence | BASING | 11.6/35 Revenue -4.3% · PAT -11.2% · OPM change -3 pp 83% evidence | 13.5/25 ROCE 2.3% · OPM 26.8% 76% evidence | 11.1/20 P/E 15.2× · PEG — 15% evidence | 6.4/20 RS sector -22.9% · RS bench -21.1% · 1Y -20.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 11.6 + 13.5 + 11.1 + 6.4 = 42.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Supernus Pharmaceuticals, Inc.SUPN | 40.7/100Mixed-negative evidence64% evidence | ASLEEP | 20.1/35 Revenue 16.3% · PAT -147.5% · OPM change 2.8 pp 62% evidence | 7.6/25 ROCE -0.8% · OPM -4% 76% evidence | 9.9/20 P/E 27.4× · PEG — 15% evidence | 3.1/20 RS sector -21.5% · RS bench -19.7% · 1Y 4.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 7.6 + 9.9 + 3.1 = 40.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21BioCryst Pharmaceuticals, Inc.BCRX | 37.2/100Thin evidence · provisional53% evidence | TURNING | 12.0/35 Revenue — · PAT — · OPM change -463.2 pp 32% evidence | 3.3/25 ROCE -230.1% · OPM -448.6% 76% evidence | 11.3/20 P/E 6.4× · PEG — 15% evidence | 10.6/20 RS sector -2.8% · RS bench -0.7% · 1Y 8.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12 + 3.3 + 11.3 + 10.6 = 37.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Hims & Hers Health, Inc.HIMS | 34.5/100Adverse evidence71% evidence | TURNING | 11.2/35 Revenue 32.8% · PAT -107.3% · OPM change -22.8 pp 83% evidence | 5.7/25 ROCE -6.9% · OPM -12.9% 76% evidence | 9.4/20 P/E 63.7× · PEG — 15% evidence | 8.2/20 RS sector -17.4% · RS bench -14.8% · 1Y -38.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 11.2 + 5.7 + 9.4 + 8.2 = 34.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Harrow, Inc.HROW | 34.4/100Thin evidence · provisional55% evidence | ASLEEP | 13.5/35 Revenue 26.3% · PAT — · OPM change -26.5 pp 62% evidence | 4.5/25 ROCE -8.7% · OPM -50% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.4/20 RS sector -14.8% · RS bench -12.9% · 1Y 15.7%5 of 12 weeks ahead 70% evidence |
| Exact sum: 13.5 + 4.5 + 10 + 6.4 = 34.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24AlvotechALVO | 31.2/100Adverse evidence65% evidence | TURNING | 9.6/35 Revenue -4.4% · PAT -183.5% · OPM change 1.1 pp 83% evidence | 8.0/25 ROCE 0.9% · OPM 9.1% 76% evidence | 9.6/20 P/E 51.3× · PEG — 15% evidence | 4.0/20 RS sector -35.5% · RS bench -33.4% · 1Y -54.6%3 of 12 weeks ahead 70% evidence |
| Exact sum: 9.6 + 8 + 9.6 + 4 = 31.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Perrigo Company plcPRGO | 27.0/100Thin evidence · provisional55% evidence | BASING | 8.3/35 Revenue -3.6% · PAT — · OPM change -42.9 pp 62% evidence | 5.0/25 ROCE -4.8% · OPM -38.4% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.7/20 RS sector -35.5% · RS bench -33.6% · 1Y -52.2%1 of 12 weeks ahead 70% evidence |
| Exact sum: 8.3 + 5 + 10 + 3.7 = 27 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Amylyx Pharmaceuticals, Inc.AMLX | 52.7/100Thin evidence · provisional43% evidence | TURNING | 17.3/35 Revenue — · PAT — · OPM change 6111.6 pp 13% evidence | 6.0/25 ROCE -18.3% · OPM — 61% evidence | 10.4/20 P/E 21× · PEG — 15% evidence | 19.0/20 RS sector 34.5% · RS bench 37.1% · 1Y 186.3%4 of 12 weeks ahead 100% evidence |
| Exact sum: 17.3 + 6 + 10.4 + 19 = 52.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27HUTCHMED (China) LimitedHCM | 38.1/100Thin evidence · provisional43% evidence | BASING | 17.3/35 Revenue — · PAT — · OPM change — 12% evidence | 8.2/25 ROCE 0% · OPM — 61% evidence | 9.0/20 P/E 107.6× · PEG — 15% evidence | 3.6/20 RS sector -27.8% · RS bench -26% · 1Y -22.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.3 + 8.2 + 9 + 3.6 = 38.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28Regencell Bioscience Holdings LimitedRGC | 30.4/100Thin evidence · provisional40% evidence | BASING | 13.4/35 Revenue — · PAT — · OPM change — 24% evidence | 7.0/25 ROCE -60.5% · OPM — 46% evidence | 10.0/20 P/E — · PEG — 0% evidence | 0.0/20 RS sector -72.7% · RS bench -72.3% · 1Y -56.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.4 + 7 + 10 + 0 = 30.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Showing 10 of 28 companies
04 · what price has already done
Market action
Liquidia Corporation has the strongest one-year price move in Drug Manufacturers - Specialty & Generic at +332.2%. It also leads on Mansfield relative strength against the S&P 500 at +89.6%. 13 of 28 covered companies are above zero on that measure. Every line covers 314 weekly closes through 2026-08-04.
Price and relative strength
Every company, the sector's own index and S&P 500 all start level on the left edge of the window, so only the distance between the lines counts — the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.
How far ahead of or behind S&P 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS S&P 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.
The same measure taken against Drug Manufacturers - Specialty & Generic itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.
05 · compare level, then change
Revenue Scale & Growth Durability
Viatris Inc. has the highest Revenue among the 28 Drug Manufacturers - Specialty & Generic companies compared here, at $14,563 million. Zoetis Inc. is next at $9,509 million. Liquidia Corporation has the highest Revenue growth at the 100% top of the scoring scale, so level and change sit with different companies.
What the numbers say: Viatris Inc. is the scale leader at $14,563 million, 53.1% ahead of Zoetis Inc.. Liquidia Corporation's growth is stored at the ≥100% scoring cap; the uncapped TTM change is 1957.1% from a $288 million base, with 19 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.
LeaderViatris Inc. · $14,563 million
Gap53.1% versus #2 · Zoetis Inc.
Persistence3/8 recent comparable periods
Coverage17/28 companies · 488 observations
Investor read: Viatris Inc. is the scale benchmark; Liquidia Corporation is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.
This conclusion weakens if: Viatris Inc.'s growth falls below Liquidia Corporation's for two consecutive comparable reports while operating margin also compresses.
Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
Revenue growthfastest growers
Revenue · company comparison
17/28 level · 17/28 change
On every company-comparison chart on this page: solid lines show level, dotted lines show change when “Both” is selected, and a missing report breaks the line rather than being invented.
All-company data · latest reported quarter
In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
Full 20-quarter history · every available company
Revenue · reported quarter history
Showing the 12 largest of 27 companies with a series here. The remaining 15 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Elanco Animal Health Incorporated · ELAN
$1.1B
$1.1B
$1.2B
$1.2B
$1.0B
$985M
$1.3B
$1.1B
$1.1B
$1.0B
$1.2B
$1.2B
$1.0B
$1.0B
$1.2B
$1.2B
$1.1B
$1.1B
$1.4B
—
Haleon plc · HLN
$2.5B
$2.5B
$2.6B
$2.6B
$2.9B
$2.8B
$3.0B
$2.8B
$2.8B
$2.8B
$2.9B
$2.8B
$2.8B
$2.8B
$2.7B
$2.7B
$2.8B
$2.8B
—
—
Hims & Hers Health, Inc. · HIMS
$74M
$85M
$101M
$114M
$145M
$167M
$191M
$208M
$227M
$247M
$278M
$316M
$402M
$481M
$586M
$545M
$599M
$618M
$608M
—
Kiniksa Pharmaceuticals International, plc · KNSA
$12M
$19M
$32M
$27M
$99M
$62M
$48M
$71M
$67M
$83M
$80M
$109M
$112M
$123M
$138M
$157M
$181M
$202M
$214M
—
Lantheus Holdings, Inc. · LNTH
$102M
$130M
$209M
$224M
$239M
$263M
$301M
$322M
$320M
$354M
$370M
$394M
$379M
$391M
$373M
$378M
$384M
$407M
$377M
—
Liquidia Corporation · LQDA
$3M
$3M
$3M
$4M
$3M
$5M
$4M
$5M
$4M
$5M
$3M
$4M
$4M
$3M
$3M
$9M
$54M
$92M
$133M
—
Neurocrine Biosciences, Inc. · NBIX
$296M
$312M
$311M
$378M
$388M
$412M
$420M
$453M
$499M
$515M
$515M
$590M
$622M
$628M
$573M
$688M
$795M
$806M
$815M
—
Teva Pharmaceutical Industries Limited · TEVA
$3.9B
$4.1B
$3.7B
$3.8B
$3.6B
$3.9B
$3.7B
$3.9B
$3.9B
$4.5B
$3.8B
$4.2B
$4.3B
$4.2B
$3.9B
$4.2B
$4.5B
$4.7B
$4.0B
—
United Therapeutics Corporation · UTHR
$445M
$415M
$462M
$467M
$516M
$492M
$507M
$597M
$609M
$615M
$678M
$715M
$749M
$736M
$794M
$799M
$800M
$790M
$782M
—
Viatris Inc. · VTRS
$4.5B
$4.3B
$4.2B
$4.1B
$4.1B
$3.9B
$3.7B
$3.9B
$3.9B
$3.8B
$3.7B
$3.8B
$3.8B
$3.5B
$3.3B
$3.6B
$3.8B
$3.7B
$3.5B
—
Zoetis Inc. · ZTS
$2.0B
$2.0B
$2.0B
$2.1B
$2.0B
$2.0B
$2.0B
$2.2B
$2.2B
$2.2B
$2.2B
$2.4B
$2.4B
$2.3B
$2.2B
$2.5B
$2.4B
$2.4B
$2.3B
—
Revenue growth · reported quarter history
Showing the 12 largest of 27 companies with a series here. The remaining 15 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Alkermes plc · ALKS
—
—
—
-9.2%
-14%
-5.9%
3.2%
124%
51%
24%
22%
-35%
-0.8%
14%
-12%
-2.0%
4.2%
-10%
28%
—
Elanco Animal Health Incorporated · ELAN
—
—
—
-8.1%
-9.3%
-11%
2.5%
-10%
4.1%
5.1%
-4.1%
12%
-3.6%
-1.5%
-1.0%
4.8%
10%
12%
15%
—
Haleon plc · HLN
—
—
14%
13%
16%
12%
14%
7.5%
-3.3%
-0.4%
-2.2%
0.8%
-0.6%
-0.3%
-6.1%
-1.3%
-0.2%
0.6%
—
—
Hims & Hers Health, Inc. · HIMS
—
—
—
87%
96%
96%
89%
82%
57%
48%
46%
52%
77%
95%
111%
72%
49%
28%
3.8%
—
Kiniksa Pharmaceuticals International, plc · KNSA
—
—
—
238%
725%
226%
50%
163%
-32%
34%
67%
54%
67%
48%
73%
44%
62%
64%
55%
—
Lantheus Holdings, Inc. · LNTH
—
—
—
122%
134%
102%
44%
44%
34%
35%
23%
22%
18%
10%
0.8%
-4.1%
1.3%
4.1%
1.1%
—
Liquidia Corporation · LQDA
—
—
—
33%
0.0%
67%
33%
25%
33%
0.0%
-25%
-20%
0.0%
-40%
0.0%
125%
1,250%
2,967%
4,333%
—
Neurocrine Biosciences, Inc. · NBIX
—
—
—
31%
31%
32%
35%
20%
29%
25%
23%
30%
25%
22%
11%
17%
28%
28%
42%
—
Teva Pharmaceutical Industries Limited · TEVA
—
—
—
-3.2%
-7.5%
-5.3%
0.0%
2.4%
7.1%
15%
4.3%
7.4%
13%
-5.1%
1.9%
0.3%
3.4%
11%
2.3%
—
United Therapeutics Corporation · UTHR
—
—
—
4.5%
16%
19%
9.7%
28%
18%
25%
34%
20%
23%
20%
17%
12%
6.8%
7.3%
-1.5%
—
Viatris Inc. · VTRS
—
—
—
-10%
-10%
-11%
-11%
-4.8%
-3.3%
-1.0%
-1.8%
-3.1%
-4.9%
-8.1%
-11%
-5.7%
0.2%
5.0%
8.1%
—
Zoetis Inc. · ZTS
—
—
—
5.3%
0.6%
3.7%
0.7%
6.2%
7.4%
8.5%
9.5%
8.3%
11%
4.7%
0.4%
4.2%
0.5%
3.0%
2.9%
—
06 · compare level, then change
Operating Economics & Margin Trend
Liquidia Corporation has the highest OPM among the 28 Drug Manufacturers - Specialty & Generic companies compared here, at 46.3%. Indivior Pharmaceuticals, Inc. is next at 43.2%. Amylyx Pharmaceuticals, Inc. has the highest Margin change at +6111.6 percentage points, so level and change sit with different companies. 25 of 28 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Liquidia Corporation leads opm at 46.3%; Amylyx Pharmaceuticals, Inc. leads margin change at +6111.6 percentage points.
LeaderLiquidia Corporation · 46.3%
Gap7.2% versus #2 · Indivior Pharmaceuticals, Inc.
Persistence4/8 recent comparable periods
Coverage25/28 companies · 468 observations
Investor read: Liquidia Corporation sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current margin change signal.
Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
OPMhighest
Margin changefastest expanders
Operating margin · company comparison
25/28 level · 26/28 change
All-company data · latest reported quarter
| Company | OPM | Margin change | Reported |
|---|---|---|---|
| Liquidia Corporation LQDA | 46% | +1,181.7 pp | Mar 2026 |
| Indivior Pharmaceuticals, Inc. INDV | 43% | +18.4 pp | Mar 2026 |
| United Therapeutics Corporation UTHR | 42% | −6.5 pp | Mar 2026 |
| Zoetis Inc. ZTS | 35% | −1.5 pp | Mar 2026 |
| Teva Pharmaceutical Industries Limited TEVA | 34% | +4.2 pp | Jun 2026 |
| Prestige Consumer Healthcare Inc. PBH | 27% | −3.0 pp | Mar 2026 |
| Neurocrine Biosciences, Inc. NBIX | 24% | +19.6 pp | Jun 2026 |
| Haleon plc HLN | 22% | +9.1 pp | Jun 2026 |
| Lantheus Holdings, Inc. LNTH | 22% | −5.8 pp | Mar 2026 |
| Amneal Pharmaceuticals, Inc. AMRX | 20% | +5.2 pp | Jun 2026 |
| ANI Pharmaceuticals, Inc. ANIP | 16% | +3.1 pp | Mar 2026 |
| Kiniksa Pharmaceuticals International, plc KNSA | 14% | +4.1 pp | Jun 2026 |
| Trulieve Cannabis Corp. TRLV | 12% | +0.6 pp | Mar 2026 |
| Phibro Animal Health Corporation PAHC | 12% | +2.0 pp | Mar 2026 |
| Elanco Animal Health Incorporated ELAN | 11% | +2.1 pp | Mar 2026 |
| Xeris Biopharma Holdings, Inc. XERS | 9.5% | +14.6 pp | Mar 2026 |
| Alvotech ALVO | 9.1% | +1.1 pp | Mar 2026 |
| Viatris Inc. VTRS | -2.3% | +86.3 pp | Mar 2026 |
| Supernus Pharmaceuticals, Inc. SUPN | -4.0% | +2.8 pp | Mar 2026 |
| Alkermes plc ALKS | -12% | −16.8 pp | Jun 2026 |
| Hims & Hers Health, Inc. HIMS | -13% | −22.8 pp | Mar 2026 |
| Bausch Health Companies Inc. BHC | -38% | −49.8 pp | Jun 2026 |
| Perrigo Company plc PRGO | -38% | −42.9 pp | Mar 2026 |
| Harrow, Inc. HROW | -50% | −26.5 pp | Mar 2026 |
| Amylyx Pharmaceuticals, Inc. AMLX | -138% | +6,111.6 pp | Mar 2026 |
| BioCryst Pharmaceuticals, Inc. BCRX | -449% | −463.2 pp | Mar 2026 |
Full 20-quarter history · every available company
OPM · reported quarter history
Showing the 12 largest of 26 companies with a series here. The remaining 14 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Alkermes plc · ALKS
-6.7%
4.3%
-9.5%
-13%
-24%
-1.8%
-3.8%
46%
23%
15%
12%
28%
28%
38%
4.5%
24%
23%
15%
-12%
—
Elanco Animal Health Incorporated · ELAN
-6.2%
-6.3%
10%
4.5%
1.6%
-2.7%
14%
-0.5%
-96%
-5.8%
6.5%
2.8%
-2.2%
-0.5%
8.4%
5.9%
0.2%
-16%
11%
—
Haleon plc · HLN
20%
16%
18%
17%
20%
13%
21%
19%
21%
9.8%
22%
18%
25%
13%
22%
22%
22%
22%
—
—
Hims & Hers Health, Inc. · HIMS
-37%
-26%
-17%
-18%
-14%
-6.9%
-5.9%
-4.4%
-3.8%
-0.2%
3.6%
3.5%
5.6%
3.9%
9.9%
4.9%
2.0%
1.5%
-13%
—
Kiniksa Pharmaceuticals International, plc · KNSA
-254%
-193%
-72%
-72%
47%
9.8%
-23%
-4.4%
-16%
0.1%
-21%
-0.1%
-8.6%
-16%
9.6%
13%
13%
9.8%
14%
—
Lantheus Holdings, Inc. · LNTH
-14%
-27%
28%
28%
36%
-65%
-3.1%
39%
35%
39%
29%
26%
35%
29%
27%
23%
11%
19%
22%
—
Liquidia Corporation · LQDA
-223%
-353%
-414%
-229%
-279%
-121%
-206%
-477%
-405%
-583%
-969%
-743%
-656%
—
—
-424%
3.3%
22%
46%
—
Neurocrine Biosciences, Inc. · NBIX
15%
-12%
1.0%
15%
23%
25%
-27%
16%
28%
29%
19%
25%
30%
23%
4.1%
21%
30%
26%
24%
—
Teva Pharmaceutical Industries Limited · TEVA
16%
1.9%
-20%
-25%
12%
-23%
-0.4%
-17%
8.7%
17%
-5.7%
-0.2%
-1.6%
-0.7%
30%
11%
20%
6.4%
34%
—
United Therapeutics Corporation · UTHR
51%
41%
62%
43%
61%
36%
56%
53%
54%
42%
53%
45%
46%
49%
48%
46%
49%
45%
42%
—
Viatris Inc. · VTRS
7.9%
-1.8%
17%
13%
14%
-5.2%
11%
9.4%
12%
-12%
5.6%
-6.3%
6.0%
-5.1%
-89%
6.5%
4.8%
-5.2%
-2.3%
—
Zoetis Inc. · ZTS
36%
30%
40%
35%
36%
34%
35%
38%
36%
32%
36%
37%
38%
33%
37%
39%
39%
34%
35%
—
Margin change · reported quarter history
Showing the 12 largest of 26 companies with a series here. The remaining 14 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Alkermes plc · ALKS
—
—
—
−14.0 pp
−17.3 pp
−6.1 pp
+5.7 pp
+58.1 pp
+47.4 pp
+16.3 pp
+16.2 pp
−18.1 pp
+4.3 pp
+23.3 pp
−7.9 pp
−3.7 pp
−5.1 pp
−22.7 pp
−16.8 pp
—
Elanco Animal Health Incorporated · ELAN
—
—
—
+18.3 pp
+7.8 pp
+3.6 pp
+3.3 pp
−5.0 pp
−97.6 pp
−3.1 pp
−7.2 pp
+3.3 pp
+93.8 pp
+5.3 pp
+1.9 pp
+3.1 pp
+2.4 pp
−15.1 pp
+2.1 pp
—
Haleon plc · HLN
—
—
+2.6 pp
−0.2 pp
−0.7 pp
−3.1 pp
+3.3 pp
+1.8 pp
+1.2 pp
−3.0 pp
+1.4 pp
−0.8 pp
+4.5 pp
+2.9 pp
−0.4 pp
+4.1 pp
−3.6 pp
+9.1 pp
—
—
Hims & Hers Health, Inc. · HIMS
—
—
—
+10.9 pp
+23.5 pp
+18.6 pp
+10.8 pp
+13.4 pp
+10.0 pp
+6.7 pp
+9.5 pp
+7.9 pp
+9.4 pp
+4.1 pp
+6.3 pp
+1.4 pp
−3.6 pp
−2.4 pp
−22.8 pp
—
Kiniksa Pharmaceuticals International, plc · KNSA
—
—
—
+454.6 pp
+300.4 pp
+202.6 pp
+49.2 pp
+67.4 pp
−63.1 pp
−9.7 pp
+2.5 pp
+4.3 pp
+7.7 pp
−15.8 pp
+30.3 pp
+13.0 pp
+21.9 pp
+25.5 pp
+4.1 pp
—
Lantheus Holdings, Inc. · LNTH
—
—
—
+54.8 pp
+49.8 pp
−37.9 pp
−31.3 pp
+10.3 pp
−0.7 pp
+104.0 pp
+31.9 pp
−12.5 pp
+0.2 pp
−9.7 pp
−1.4 pp
−2.8 pp
−23.9 pp
−10.1 pp
−5.8 pp
—
Liquidia Corporation · LQDA
—
—
—
−40.7 pp
−56.3 pp
+232.2 pp
+208.9 pp
−248.0 pp
−125.9 pp
−462.2 pp
−763.6 pp
−266.4 pp
−251.3 pp
−654.4 pp
−166.3 pp
+318.9 pp
+659.5 pp
+1,259.3 pp
+1,181.7 pp
—
Neurocrine Biosciences, Inc. · NBIX
—
—
—
−7.2 pp
+7.6 pp
+36.7 pp
−28.2 pp
+1.8 pp
+5.7 pp
+4.1 pp
+46.5 pp
+8.3 pp
+1.2 pp
−6.6 pp
−15.2 pp
−3.4 pp
+0.6 pp
+3.6 pp
+19.6 pp
—
Teva Pharmaceutical Industries Limited · TEVA
—
—
—
−40.0 pp
−4.3 pp
−24.4 pp
+19.1 pp
+8.2 pp
−3.0 pp
+39.3 pp
−5.3 pp
+16.7 pp
−10.3 pp
−17.5 pp
+35.2 pp
+11.2 pp
+21.4 pp
+7.1 pp
+4.2 pp
—
United Therapeutics Corporation · UTHR
—
—
—
−6.6 pp
+9.5 pp
−5.2 pp
−6.3 pp
+9.3 pp
−7.2 pp
+6.6 pp
−3.5 pp
−7.8 pp
−7.9 pp
+6.3 pp
−4.4 pp
+0.9 pp
+2.8 pp
−3.5 pp
−6.5 pp
—
Viatris Inc. · VTRS
—
—
—
+14.3 pp
+5.8 pp
−3.4 pp
−6.2 pp
−3.9 pp
−2.2 pp
−6.6 pp
−5.1 pp
−15.7 pp
−5.5 pp
+6.7 pp
−94.2 pp
+12.8 pp
−1.2 pp
−0.1 pp
+86.3 pp
—
Zoetis Inc. · ZTS
—
—
—
−0.8 pp
−0.3 pp
+3.6 pp
−4.2 pp
+2.6 pp
+0.6 pp
−2.0 pp
+1.0 pp
−1.3 pp
+1.9 pp
+1.2 pp
+0.5 pp
+2.4 pp
+0.5 pp
+1.0 pp
−1.5 pp
—
07 · compare level, then change
Profit Scale & Acceleration
Zoetis Inc. has the highest Net profit among the 28 Drug Manufacturers - Specialty & Generic companies compared here, at $2,643 million. United Therapeutics Corporation is next at $1,288 million. Phibro Animal Health Corporation has the highest Profit growth at the 100% top of the scoring scale, so level and change sit with different companies.
What the numbers say: Zoetis Inc. leads with $2,643 million of TTM profit, 105.2% above United Therapeutics Corporation. Phibro Animal Health Corporation shows ≥100% on the scoring scale (196.9% uncapped) growth from a $95 million profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.
LeaderZoetis Inc. · $2,643 million
Gap105.2% versus #2 · United Therapeutics Corporation
Persistence6/8 recent comparable periods
Coverage19/28 companies · 508 observations
Investor read: Zoetis Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.
Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
Profit growthfastest growers
Net profit · company comparison
19/28 level · 8/28 change
All-company data · latest reported quarter
| Company | Net profit | Profit growth | Reported |
|---|---|---|---|
| Zoetis Inc. ZTS | $601M | -0.2% | Mar 2026 |
| Haleon plc HLN | $434M | 96% | Jun 2026 |
| Teva Pharmaceutical Industries Limited TEVA | $370M | 68% | Jun 2026 |
| United Therapeutics Corporation UTHR | $275M | -15% | Mar 2026 |
| Neurocrine Biosciences, Inc. NBIX | $198M | 2,375% | Jun 2026 |
| Viatris Inc. VTRS | $176M | -235% | Mar 2026 |
| Lantheus Holdings, Inc. LNTH | $118M | 62% | Mar 2026 |
| Indivior Pharmaceuticals, Inc. INDV | $115M | 95% | Mar 2026 |
| Amneal Pharmaceuticals, Inc. AMRX | $78M | 212% | Jun 2026 |
| Elanco Animal Health Incorporated ELAN | $57M | -15% | Mar 2026 |
| Prestige Consumer Healthcare Inc. PBH | $54M | 8.0% | Mar 2026 |
| Liquidia Corporation LQDA | $53M | — | Mar 2026 |
| ANI Pharmaceuticals, Inc. ANIP | $29M | 81% | Mar 2026 |
| Phibro Animal Health Corporation PAHC | $24M | 14% | Mar 2026 |
| Kiniksa Pharmaceuticals International, plc KNSA | $23M | 156% | Jun 2026 |
| Trulieve Cannabis Corp. TRLV | $2M | -705% | Mar 2026 |
| Xeris Biopharma Holdings, Inc. XERS | $2M | — | Mar 2026 |
| Alvotech ALVO | $1M | -99% | Mar 2026 |
| Supernus Pharmaceuticals, Inc. SUPN | $-2M | -127% | Mar 2026 |
| Regencell Bioscience Holdings Limited RGC | $-5M | — | Dec 2025 |
| Harrow, Inc. HROW | $-28M | 0.0% | Mar 2026 |
| HUTCHMED (China) Limited HCM | $-37M | 14,367% | Jun 2026 |
| Amylyx Pharmaceuticals, Inc. AMLX | $-41M | -860% | Mar 2026 |
| Alkermes plc ALKS | $-66M | -400% | Jun 2026 |
| Hims & Hers Health, Inc. HIMS | $-92M | -288% | Mar 2026 |
| Perrigo Company plc PRGO | $-390M | -100% | Mar 2026 |
| BioCryst Pharmaceuticals, Inc. BCRX | $-722M | — | Mar 2026 |
| Bausch Health Companies Inc. BHC | $-1.4B | -174% | Jun 2026 |
Full 20-quarter history · every available company
Net profit · reported quarter history
Showing the 12 largest of 28 companies with a series here. The remaining 16 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Alkermes plc · ALKS
$-29M
$1M
$-45M
$-30M
$-67M
$-22M
$-12M
$279M
$92M
$161M
$39M
$95M
$93M
$146M
$22M
$87M
$83M
$49M
$-66M
—
Elanco Animal Health Incorporated · ELAN
$-104M
$-108M
$51M
$-10M
$-65M
$-54M
$103M
$-97M
$-1.1B
$-141M
$32M
$-50M
$364M
$-8M
$67M
$11M
$-34M
$-276M
$57M
—
Haleon plc · HLN
$382M
$537M
$357M
$187M
$365M
$210M
$415M
$315M
$374M
$7M
$441M
$313M
$499M
$222M
$407M
$407M
$434M
$434M
—
—
Hims & Hers Health, Inc. · HIMS
$-16M
$-31M
$-16M
$-20M
$-19M
$-11M
$-10M
$-7M
$-8M
$1M
$11M
$13M
$76M
$26M
$49M
$43M
$16M
$21M
$-92M
—
Kiniksa Pharmaceuticals International, plc · KNSA
$-31M
$-36M
$-25M
$-20M
$224M
$4M
$-12M
$15M
$-14M
$25M
$-18M
$-4M
$-13M
$-9M
$9M
$18M
$18M
$14M
$23M
—
Lantheus Holdings, Inc. · LNTH
$-13M
$-40M
$43M
$43M
$61M
$-119M
$-3M
$94M
$132M
$103M
$131M
$62M
$131M
$-12M
$73M
$79M
$28M
$54M
$118M
—
Liquidia Corporation · LQDA
$-7M
$-12M
$-16M
$-9M
$-9M
$-7M
$-12M
$-24M
$-16M
$-27M
$-30M
$-29M
$-31M
$-39M
$-38M
$-42M
$-4M
$15M
$53M
—
Neurocrine Biosciences, Inc. · NBIX
$23M
$-7M
$14M
$-17M
$69M
$89M
$-77M
$96M
$83M
$148M
$43M
$65M
$130M
$103M
$8M
$108M
$210M
$154M
$198M
—
Teva Pharmaceutical Industries Limited · TEVA
$306M
$-151M
$-973M
$-260M
$59M
$-1.3B
$-253M
$-907M
$76M
$466M
$-415M
$-876M
$-393M
$-276M
$220M
$281M
$432M
$469M
$370M
—
United Therapeutics Corporation · UTHR
$163M
$112M
$240M
$116M
$239M
$132M
$241M
$259M
$268M
$217M
$307M
$278M
$309M
$301M
$322M
$310M
$339M
$364M
$275M
—
Viatris Inc. · VTRS
$312M
$-264M
$399M
$314M
$354M
$1.0B
$225M
$264M
$332M
$-766M
$114M
$-326M
$95M
$-517M
$-3.0B
$-5M
$-128M
$-340M
$176M
—
Zoetis Inc. · ZTS
$552M
$413M
$594M
$529M
$528M
$460M
$551M
$670M
$596M
$523M
$599M
$624M
$692M
$581M
$602M
$718M
$721M
$603M
$601M
—
Profit growth · reported quarter history
Showing the 12 largest of 24 companies with a series here. The remaining 12 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Alkermes plc · ALKS
—
—
—
-1,600%
—
-2,300%
—
—
—
—
—
-66%
1.1%
-9.3%
-44%
-8.4%
-11%
-66%
-400%
—
Amneal Pharmaceuticals, Inc. · AMRX
—
—
—
-850%
—
—
—
—
—
—
—
-43%
-52%
—
—
112%
50%
—
212%
—
Elanco Animal Health Incorporated · ELAN
—
—
—
—
—
—
102%
—
—
—
-69%
—
—
—
109%
—
-109%
—
-15%
—
Haleon plc · HLN
—
—
43%
-31%
-4.5%
-61%
16%
68%
2.5%
-97%
6.3%
-0.6%
33%
3,071%
-7.7%
30%
-13%
96%
—
—
Hims & Hers Health, Inc. · HIMS
—
—
—
—
—
—
—
—
—
—
—
—
—
2,500%
345%
231%
-79%
-19%
-288%
—
Kiniksa Pharmaceuticals International, plc · KNSA
—
—
—
—
—
—
—
—
-106%
525%
—
-127%
—
-136%
—
—
—
—
156%
—
Lantheus Holdings, Inc. · LNTH
—
—
—
—
—
—
-107%
119%
116%
—
—
-34%
-0.8%
-112%
-44%
27%
-79%
—
62%
—
Neurocrine Biosciences, Inc. · NBIX
—
—
—
-140%
200%
—
-650%
—
20%
66%
—
-32%
57%
-30%
-81%
66%
62%
50%
2,375%
—
Teva Pharmaceutical Industries Limited · TEVA
—
—
—
-224%
-81%
—
—
—
29%
—
—
—
-617%
-159%
—
—
—
—
68%
—
United Therapeutics Corporation · UTHR
—
—
—
-33%
47%
18%
0.4%
123%
12%
64%
27%
7.3%
15%
39%
4.9%
12%
9.7%
21%
-15%
—
Viatris Inc. · VTRS
—
—
—
—
13%
—
-44%
-16%
-6.2%
-176%
-49%
-223%
-71%
—
-2,768%
—
-235%
—
—
—
Zoetis Inc. · ZTS
—
—
—
3.5%
-4.4%
11%
-7.2%
27%
13%
14%
8.7%
-6.9%
16%
11%
0.5%
15%
4.2%
3.8%
-0.2%
—
08 · compare level, then change
Return On Capital Employed
Indivior Pharmaceuticals, Inc. has the highest ROCE among the 28 Drug Manufacturers - Specialty & Generic companies compared here, at 34.8%. Liquidia Corporation is next at 29.4%. Liquidia Corporation has the highest ROCE change at +50.1 percentage points, so level and change sit with different companies. 28 of 28 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Indivior Pharmaceuticals, Inc. leads ROCE at 34.8%, 5.4 percentage points above Liquidia Corporation. Liquidia Corporation has the strongest latest improvement at +50.1 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.
LeaderIndivior Pharmaceuticals, Inc. · 34.8%
Gap18.4% versus #2 · Liquidia Corporation
Persistence7/8 recent comparable periods
Coverage28/28 companies · 535 observations
Investor read: Indivior Pharmaceuticals, Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current roce change signal.
ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCEhighest
ROCE changefastest improvers
Return on capital · company comparison
28/28 level · 28/28 change
All-company data · latest reported quarter
| Company | ROCE | ROCE change | Reported |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. INDV | 35% | +29.9 pp | Mar 2026 |
| Liquidia Corporation LQDA | 29% | +50.1 pp | Mar 2026 |
| Zoetis Inc. ZTS | 6.7% | −0.3 pp | Mar 2026 |
| Trulieve Cannabis Corp. TRLV | 5.6% | +2.6 pp | Mar 2026 |
| United Therapeutics Corporation UTHR | 5.0% | −1.0 pp | Mar 2026 |
| Amneal Pharmaceuticals, Inc. AMRX | 5.0% | +0.3 pp | Jun 2026 |
| Lantheus Holdings, Inc. LNTH | 4.3% | −1.7 pp | Mar 2026 |
| Kiniksa Pharmaceuticals International, plc KNSA | 4.3% | +0.3 pp | Jun 2026 |
| Phibro Animal Health Corporation PAHC | 4.0% | +0.4 pp | Mar 2026 |
| Neurocrine Biosciences, Inc. NBIX | 3.9% | −0.8 pp | Jun 2026 |
| Bausch Health Companies Inc. BHC | 3.5% | +1.5 pp | Jun 2026 |
| ANI Pharmaceuticals, Inc. ANIP | 3.4% | +0.6 pp | Mar 2026 |
| Xeris Biopharma Holdings, Inc. XERS | 3.2% | +4.5 pp | Mar 2026 |
| Prestige Consumer Healthcare Inc. PBH | 2.3% | −0.4 pp | Mar 2026 |
| Haleon plc HLN | 2.2% | 0.0 pp | Jun 2026 |
| Elanco Animal Health Incorporated ELAN | 1.2% | +0.4 pp | Mar 2026 |
| Alvotech ALVO | 0.9% | −0.3 pp | Mar 2026 |
| Alkermes plc ALKS | 0.7% | −4.7 pp | Jun 2026 |
| HUTCHMED (China) Limited HCM | 0.0% | +0.2 pp | Jun 2026 |
| Viatris Inc. VTRS | -0.3% | +7.7 pp | Mar 2026 |
| Supernus Pharmaceuticals, Inc. SUPN | -0.8% | +0.2 pp | Mar 2026 |
| Teva Pharmaceutical Industries Limited TEVA | -0.9% | −2.5 pp | Jun 2026 |
| Perrigo Company plc PRGO | -4.8% | −5.3 pp | Mar 2026 |
| Hims & Hers Health, Inc. HIMS | -6.9% | −18.9 pp | Mar 2026 |
| Harrow, Inc. HROW | -8.7% | −3.5 pp | Mar 2026 |
| Amylyx Pharmaceuticals, Inc. AMLX | -18% | −4.0 pp | Mar 2026 |
| Regencell Bioscience Holdings Limited RGC | -61% | −49.5 pp | Dec 2025 |
| BioCryst Pharmaceuticals, Inc. BCRX | -230% | −236.3 pp | Mar 2026 |
Full 20-quarter history · every available company
ROCE · reported quarter history
Showing the 12 largest of 28 companies with a series here. The remaining 16 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Alkermes plc · ALKS
-1.3%
0.9%
-1.8%
-2.2%
-4.0%
7.7%
-0.7%
18%
5.5%
3.5%
2.8%
6.5%
6.0%
10%
0.8%
5.4%
5.0%
3.3%
-1.8%
0.7%
Elanco Animal Health Incorporated · ELAN
-0.5%
-0.5%
0.8%
0.4%
0.1%
-0.2%
1.2%
0.0%
-7.8%
-0.4%
0.6%
0.2%
-0.2%
0.0%
0.8%
0.6%
0.0%
-1.6%
1.2%
—
Haleon plc · HLN
3.4%
2.6%
2.3%
2.1%
1.9%
1.2%
1.8%
1.5%
2.0%
0.9%
2.3%
1.7%
2.4%
1.2%
2.2%
2.2%
2.2%
2.2%
2.2%
2.2%
Hims & Hers Health, Inc. · HIMS
-9.7%
-9.7%
-5.1%
-6.3%
-5.8%
-3.5%
-3.4%
-2.9%
-2.6%
-0.1%
2.9%
3.2%
5.7%
4.4%
12%
2.7%
1.1%
0.8%
-6.9%
—
Kiniksa Pharmaceuticals International, plc · KNSA
-11%
-14%
-10%
-9.5%
15%
2.0%
-3.8%
-1.0%
-2.6%
0.0%
-3.8%
0.0%
-2.2%
-4.1%
2.8%
4.0%
4.6%
3.6%
5.0%
4.3%
Lantheus Holdings, Inc. · LNTH
-1.8%
-4.5%
7.7%
8.0%
11%
-19%
-1.0%
13%
10%
11%
8.0%
7.2%
10%
7.1%
6.0%
5.0%
2.7%
4.2%
4.3%
—
Liquidia Corporation · LQDA
-8.3%
-13%
-17%
-7.8%
-8.1%
-6.3%
-8.9%
-20%
-13%
-24%
-19%
-21%
-18%
-25%
-21%
-23%
0.9%
10%
29%
—
Neurocrine Biosciences, Inc. · NBIX
3.3%
-2.2%
0.2%
3.2%
5.1%
5.7%
-5.9%
3.9%
7.4%
6.8%
4.2%
5.9%
7.0%
4.9%
0.8%
4.7%
7.1%
5.9%
5.3%
3.9%
Teva Pharmaceutical Industries Limited · TEVA
1.7%
0.2%
-2.0%
-2.7%
1.2%
-2.8%
0.0%
-2.0%
1.1%
2.4%
-0.7%
0.0%
-0.2%
-0.1%
1.8%
1.6%
3.1%
1.1%
2.4%
-0.9%
United Therapeutics Corporation · UTHR
5.2%
3.7%
6.1%
4.1%
6.2%
3.3%
5.1%
5.4%
5.6%
4.3%
6.1%
5.2%
5.5%
5.5%
6.0%
5.5%
6.0%
5.1%
5.0%
—
Viatris Inc. · VTRS
1.0%
-0.2%
1.5%
1.2%
1.3%
-0.5%
0.9%
0.9%
1.1%
-1.1%
0.5%
-0.6%
0.6%
-0.5%
-8.0%
0.7%
0.5%
-0.6%
-0.3%
—
Zoetis Inc. · ZTS
6.1%
5.0%
7.0%
6.4%
6.2%
5.8%
6.2%
7.3%
6.7%
5.8%
6.6%
7.1%
7.3%
6.6%
7.0%
8.2%
7.2%
6.7%
6.7%
—
ROCE change · reported quarter history
Showing the 12 largest of 28 companies with a series here. The remaining 16 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Alkermes plc · ALKS
—
—
—
—
−2.7 pp
+6.8 pp
+1.1 pp
+19.7 pp
+9.5 pp
−4.2 pp
+3.5 pp
−11.0 pp
+0.5 pp
+6.6 pp
−2.0 pp
−1.1 pp
−1.0 pp
−6.8 pp
−2.6 pp
−4.7 pp
Elanco Animal Health Incorporated · ELAN
—
—
—
—
+0.6 pp
+0.3 pp
+0.4 pp
−0.4 pp
−7.9 pp
−0.2 pp
−0.6 pp
+0.2 pp
+7.6 pp
+0.4 pp
+0.2 pp
+0.4 pp
+0.2 pp
−1.6 pp
+0.4 pp
—
Haleon plc · HLN
—
—
—
—
−1.5 pp
−1.4 pp
−0.5 pp
−0.6 pp
+0.1 pp
−0.3 pp
+0.5 pp
+0.2 pp
+0.4 pp
+0.3 pp
−0.1 pp
+0.5 pp
−0.2 pp
+1.0 pp
0.0 pp
0.0 pp
Hims & Hers Health, Inc. · HIMS
—
—
—
—
+3.9 pp
+6.2 pp
+1.7 pp
+3.4 pp
+3.2 pp
+3.4 pp
+6.3 pp
+6.1 pp
+8.3 pp
+4.5 pp
+9.1 pp
−0.5 pp
−4.6 pp
−3.6 pp
−18.9 pp
—
Kiniksa Pharmaceuticals International, plc · KNSA
—
—
—
—
+25.5 pp
+16.3 pp
+6.4 pp
+8.5 pp
−17.5 pp
−2.0 pp
0.0 pp
+1.0 pp
+0.4 pp
−4.1 pp
+6.6 pp
+4.0 pp
+6.8 pp
+7.7 pp
+2.2 pp
+0.3 pp
Lantheus Holdings, Inc. · LNTH
—
—
—
—
+12.3 pp
−14.1 pp
−8.7 pp
+4.5 pp
−0.3 pp
+29.4 pp
+9.0 pp
−5.3 pp
0.0 pp
−3.7 pp
−2.0 pp
−2.2 pp
−7.5 pp
−2.9 pp
−1.7 pp
—
Liquidia Corporation · LQDA
—
—
—
—
+0.2 pp
+6.7 pp
+8.5 pp
−11.7 pp
−5.2 pp
−17.7 pp
−10.5 pp
−1.8 pp
−5.0 pp
−1.0 pp
−1.3 pp
−1.3 pp
+19.2 pp
+35.4 pp
+50.1 pp
—
Neurocrine Biosciences, Inc. · NBIX
—
—
—
—
+1.8 pp
+7.9 pp
−6.1 pp
+0.7 pp
+2.3 pp
+1.1 pp
+10.1 pp
+2.0 pp
−0.4 pp
−1.9 pp
−3.4 pp
−1.2 pp
+0.1 pp
+1.0 pp
+4.5 pp
−0.8 pp
Teva Pharmaceutical Industries Limited · TEVA
—
—
—
—
−0.5 pp
−3.0 pp
+2.0 pp
+0.7 pp
−0.1 pp
+5.2 pp
−0.7 pp
+2.0 pp
−1.3 pp
−2.5 pp
+2.5 pp
+1.6 pp
+3.3 pp
+1.2 pp
+0.6 pp
−2.5 pp
United Therapeutics Corporation · UTHR
—
—
—
—
+1.0 pp
−0.4 pp
−1.0 pp
+1.3 pp
−0.6 pp
+1.0 pp
+1.0 pp
−0.2 pp
−0.1 pp
+1.2 pp
−0.1 pp
+0.3 pp
+0.5 pp
−0.4 pp
−1.0 pp
—
Viatris Inc. · VTRS
—
—
—
—
+0.3 pp
−0.3 pp
−0.6 pp
−0.3 pp
−0.2 pp
−0.6 pp
−0.4 pp
−1.5 pp
−0.5 pp
+0.6 pp
−8.5 pp
+1.3 pp
−0.1 pp
−0.1 pp
+7.7 pp
—
Zoetis Inc. · ZTS
—
—
—
—
+0.1 pp
+0.8 pp
−0.8 pp
+0.9 pp
+0.5 pp
0.0 pp
+0.4 pp
−0.2 pp
+0.6 pp
+0.8 pp
+0.4 pp
+1.1 pp
−0.1 pp
+0.1 pp
−0.3 pp
—
09 · compare level, then change
Valuation Against Growth & Quality
Lantheus Holdings, Inc. has the lowest PEG among the 28 Drug Manufacturers - Specialty & Generic companies compared here, at 1.02×. Phibro Animal Health Corporation is next at 1.31×. Trulieve Cannabis Corp. has the lowest P/E at -13.3×, so level and change sit with different companies. 4 of 28 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Lantheus Holdings, Inc. has the lowest comparable PEG at 1.02×, 22.1% below Phibro Animal Health Corporation. Only 4 of 28 companies have earnings and growth steady enough for the ratio to mean anything, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.
LeaderLantheus Holdings, Inc. · 1.02×
Gap22.1% versus #2 · Phibro Animal Health Corporation
Persistence0/8 recent comparable periods
Coverage4/28 companies · 38 observations
Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.
This conclusion weakens if: The next two comparable reports reverse the current p/e signal.
PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.
PEGlowest PEG
P/Elowest P/E
Valuation · company comparison
4/28 level · 25/28 change
All-company data · latest reported quarter
Full 20-quarter history · every available company
PEG · reported quarter history
Alkermes plc · ALKS
—
—
—
—
—
—
—
—
—
—
—
—
0.2
—
—
0.6
—
—
—
—
Haleon plc · HLN
—
—
—
—
—
—
—
—
—
—
—
—
—
0.7
0.7
0.6
0.9
1.0
—
—
Hims & Hers Health, Inc. · HIMS
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
4.6
—
—
—
Lantheus Holdings, Inc. · LNTH
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
1.0
—
Neurocrine Biosciences, Inc. · NBIX
—
—
—
—
—
—
—
—
—
0.9
—
—
—
1.2
—
—
2.8
0.7
—
—
Phibro Animal Health Corporation · PAHC
—
—
—
—
—
—
—
—
—
—
—
—
—
1.3
—
—
—
—
—
—
United Therapeutics Corporation · UTHR
—
—
—
—
—
—
—
0.4
0.5
0.4
0.3
0.6
0.6
0.6
0.7
0.6
1.0
1.3
2.7
—
Zoetis Inc. · ZTS
—
—
—
—
—
—
—
4.6
2.9
3.1
1.9
4.6
4.5
3.8
5.0
2.2
2.4
2.4
2.0
—
P/E · reported quarter history
Showing the 12 largest of 25 companies with a series here. The remaining 13 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Alkermes plc · ALKS
—
—
—
—
—
—
—
50.6
21.8
13.3
10.5
13.9
13.6
12.7
15.4
13.6
14.6
19.2
38.5
132.8
Elanco Animal Health Incorporated · ELAN
—
—
—
—
—
—
—
—
—
—
—
—
36.7
17.8
14.2
16.6
335.7
—
—
—
Haleon plc · HLN
—
—
—
—
10.9
28.7
18.4
24.8
25.2
28.4
28.4
27.6
29.9
24.1
25.3
22.5
20.3
20.1
20.6
19.3
Hims & Hers Health, Inc. · HIMS
—
—
—
—
—
—
—
—
—
—
—
252.4
41.9
45.6
42.8
62.3
105.0
63.7
—
—
Kiniksa Pharmaceuticals International, plc · KNSA
—
—
—
—
6.4
5.8
3.9
4.3
—
87.7
179.4
—
—
—
—
691.8
86.3
55.0
86.0
101.5
Lantheus Holdings, Inc. · LNTH
—
—
—
153.6
47.2
127.4
—
204.7
48.6
13.3
9.5
13.2
18.3
20.5
27.7
21.8
21.6
19.5
18.3
—
Liquidia Corporation · LQDA
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
269.6
—
Neurocrine Biosciences, Inc. · NBIX
21.0
92.6
130.2
886.2
186.3
76.6
168.7
54.5
60.5
53.3
38.0
41.6
30.9
41.5
37.5
37.2
33.6
30.4
20.3
24.7
Teva Pharmaceutical Industries Limited · TEVA
14.8
21.1
—
—
—
—
—
—
—
—
—
—
—
—
—
—
33.7
25.8
22.7
56.5
United Therapeutics Corporation · UTHR
18.7
21.5
12.4
17.8
14.2
18.5
15.1
12.5
12.4
11.1
10.9
14.6
15.7
14.3
12.3
11.2
15.9
17.5
21.9
—
Viatris Inc. · VTRS
—
—
15.8
8.9
7.0
6.5
17.2
19.2
19.7
216.6
—
—
—
—
—
—
—
—
—
—
Zoetis Inc. · ZTS
46.8
57.2
43.3
39.0
33.9
32.6
37.6
36.2
35.4
38.9
32.6
33.9
36.7
29.8
29.9
27.2
24.9
20.9
19.6
—
10 · before the conclusion, check the blind spots
What can make this comparison misleading?
This Drug Manufacturers - Specialty & Generic comparison names 5 specific ways its own evidence can mislead, all listed below. 1 of the 28 companies reports on an older date than the sector's freshest reporters, so its rank is marked stale. A high growth rate can still be a low-base artefact.
Keep these limits visible
- A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
- A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
- The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- 1 company has an older fundamental reporting date than the sector’s freshest reporters; its rank carries a stale marker.
11 · evidence and freshness
How was this comparison built?
This comparison is built from the reported filings of 28 Drug Manufacturers - Specialty & Generic companies, normalized to a common $ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Jun 2026 and market data through 2026-08-04.
FundamentalsThrough Jun 2026 · up to 20 quarters per company
Market dataThrough 2026-08-04 · weekly price and relative-strength history
Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
12 · questions investors ask, short speakable answers
Drug Manufacturers - Specialty & Generic company comparison FAQs
These 22 answers restate the Drug Manufacturers - Specialty & Generic comparison above in question form. Every one is computed from the same 28 companies and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-08-04. Nothing here is estimated, and none of it is a recommendation.
Is the Drug Manufacturers - Specialty & Generic sector outperforming S&P 500?
Drug Manufacturers - Specialty & Generic has outperformed S&P 500 by 15% over 52 weeks and 1.6% over 13 weeks. 13 of 28 covered companies beat the S&P 500 on Mansfield relative strength, while 10 of 28 beat the sector itself.
Which Drug Manufacturers - Specialty & Generic company is largest by revenue?
Viatris Inc. leads with revenue of $14,563 million, based on 17 of 28 comparable companies through Mar 2026.
Which Drug Manufacturers - Specialty & Generic company is growing fastest?
Liquidia Corporation has the fastest current revenue growth at 100%, across 17 of 28 comparable companies.
Which Drug Manufacturers - Specialty & Generic company has the strongest 4-Factor Sector Score?
Liquidia Corporation ranks first at 72.3/100 with 63.6% evidence confidence. The score prioritizes research; it is not a buy recommendation.
Which Drug Manufacturers - Specialty & Generic company has the lowest comparable PEG?
Lantheus Holdings, Inc. has the lowest comparable PEG at 1.02, among 4 of 28 companies whose earnings and growth are steady enough for the ratio to mean anything.
How much history does this Drug Manufacturers - Specialty & Generic comparison include?
The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.
How is the 4-Factor Sector Score calculated?
The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.
Which Drug Manufacturers - Specialty & Generic company is the biggest?
Viatris Inc. is the largest, with trailing-twelve-month revenue of $14,563 million, ahead of Zoetis Inc. at $9,509 million. That covers 17 of 28 companies with comparable reporting through Mar 2026.
Which Drug Manufacturers - Specialty & Generic company has the best profit margins?
Liquidia Corporation has the highest operating margin at 46.3%, from 25 of 28 comparable companies. Amylyx Pharmaceuticals, Inc. shows the biggest recent improvement, at +6111.6 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.
Which Drug Manufacturers - Specialty & Generic company makes the most profit?
Zoetis Inc. earns the most, at $2,643 million of trailing-twelve-month net profit, from 19 of 28 comparable companies. Phibro Animal Health Corporation has the fastest profit growth at 100%, though growth off a small or recovering profit base overstates how much has actually changed.
Which Drug Manufacturers - Specialty & Generic company earns the highest return on capital?
Indivior Pharmaceuticals, Inc. leads on return on capital employed at 34.8%, across 28 of 28 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.
Which Drug Manufacturers - Specialty & Generic stock is the cheapest?
On PEG — where a LOWER number is cheaper — Lantheus Holdings, Inc. screens cheapest at 1.02×. Only 4 of 28 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.
Is the Drug Manufacturers - Specialty & Generic sector beating the market?
Drug Manufacturers - Specialty & Generic has outperformed S&P 500 by 15% over the last 52 weeks and 1.6% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 13 of 28 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.
Which Drug Manufacturers - Specialty & Generic stock has the strongest price momentum?
Liquidia Corporation has the strongest relative strength against S&P 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.
Which Drug Manufacturers - Specialty & Generic company scores highest for research priority?
Liquidia Corporation scores 72.3 out of 100 with 63.6% evidence confidence, from 25.7 points on growth and earnings, 18 on capital efficiency, 8.6 on valuation and 20 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.
How many Drug Manufacturers - Specialty & Generic companies does this comparison cover, and over what period?
It compares 28 listed companies over up to 20 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.
What is the total market cap of the Drug Manufacturers - Specialty & Generic sector?
The 28 Drug Manufacturers - Specialty & Generic companies on this page carry $260,847 million of combined market value. Haleon plc is the largest at $42,367 million, about 16% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-04.
What is the Drug Manufacturers - Specialty & Generic sector's P/E ratio?
The median price-to-earnings ratio across the 28 Drug Manufacturers - Specialty & Generic companies on this page is 27.4×, measured on the 24 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 2026-08-04.
How is the Drug Manufacturers - Specialty & Generic sector performing?
13 of the 28 covered Drug Manufacturers - Specialty & Generic companies are beating S&P 500 on Mansfield relative strength. The sector itself is 15% ahead of S&P 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-04.
How many Drug Manufacturers - Specialty & Generic stocks are listed in the US?
This comparison covers 28 listed Drug Manufacturers - Specialty & Generic companies in the US, each above the size floor the site applies. The full ranked list is on this page, with reported fundamentals through Jun 2026. Membership is the full industry list — nothing is dropped for having thin data.
Why are some values on this page blank?
A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.
Is this investment advice?
No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.